Patents Examined by Carla J. Myers
  • Method for treating idiopathic pulmonary fibrosis
    Patent number: 10543185
    Abstract: Aspects of the disclosure relate to a method for treating idiopathic pulmonary fibrosis (IPF) in a patient with N-acetylcysteine (NAC) comprising administering NAC to a patient after a sample from the patient has been genotyped and determined to be any one of: a) homozygous or heterozygous for a thymine at the single nucleotide polymorphism rs3750920; b) homozygous or heterozygous for guanine at the single nucleotide polymorphism rs5743894; or c) homozygous or heterozygous for thymine at the single nucleotide polymorphism rs35705950.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: January 28, 2020
    Assignees: The University of Chicago, Cornell University
    Inventors: Imre Noth, Justin Oldham, Fernando Martinez
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10538810
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene KIAA1199 is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene KIAA1199 and optionally one or more further marker genes selected from DMBT1, TMSB15A, DPP6, SLC51B, NUDT11, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR110, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAMS, HYAL2, AHRR, CXCL3, CYP1A1, CYP1B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: January 21, 2020
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • 3.beta-hydroxysteroid dehydrogenase in steroid dependent disease
    Patent number: 10533228
    Abstract: Methods and kits for characterizing a subject having a steroid-dependent disease such as prostate cancer are described. A method of treating a steroid-dependent disease in a subject by obtaining a biological sample from the subject, determining if the HSD3B1(1245C) gene or 3?HSD1(367T) protein is expressed in the biological sample, and providing treatment other than or in addition to steroid ablation to the subject if the HSD3B1(1245C) gene or 3?HSD1(367T) protein is expressed is also described.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: January 14, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Nima Sharifi, Kai-Hsiung Chang
  • Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
    Patent number: 10526656
    Abstract: The present invention relates to in vitro methods for the diagnosis of chronic obstructive pulmonary disease (COPD), wherein the expression of the marker gene TMSB15A is determined. In particular, the invention relates to an in vitro diagnostic method of assessing the susceptibility of a subject to develop progressive COPD involving the appearance of irreversible lung damage, wherein the expression of the marker gene TMSB15A and optionally one or more further marker genes selected from DMBT1, KIAA1 T99, DPP6, SLC51 B, NUDT1 1, ELF5, AZGP1, PRRX1, AQP3, SFN, GPR1 10, GDF15, RASGRF2, RND1, PLA1A, FGG, CEACAM5, HYAL2, AHRR, CXCL3, CYP1A1, CYP1 B1, CYP1A2, CST6, NTRK2, COMP, ITGA10, CTHRC1, TAL1, FIBIN, BEX5, BEX1, ESM1 and GHRL is determined.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: January 7, 2020
    Assignee: Transgenion—International Institute for Regenerative Translational Medicine GmbH
    Inventor: Rolf Ziesche
  • Methylation markers for diagnosing hepatocellular carcinoma and lung cancer
    Patent number: 10513739
    Abstract: Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are methods of determining the prognosis of the subject having HCC or lung cancer. In additional instances, described herein are methods of determining the specific staging of HCC or lung cancer in a subject.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 24, 2019
    Assignees: YouHealth Oncotech, Limited, The Regents of the University of California
    Inventors: Kang Zhang, Rui Hou, Lianghong Zheng
  • Assays for diagnosing type 1 diabetes
    Patent number: 10508308
    Abstract: Described herein are compositions and methods for diagnosing or monitoring type 1 diabetes.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: December 17, 2019
    Assignee: L2 Disgnostics, LLC
    Inventor: Sahar Usmani-Brown
  • Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
    Patent number: 10501803
    Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: December 10, 2019
    Assignees: MAX-PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN
    Inventors: Guillermo Barreto, Aditi Mehta, Indrabahadur Singh, Marten Szibor, Rajkumar Savai, Werner Seeger, Thomas Braun, Andreas Günther, Marcus Krüger
  • Differential methylation level of CPG loci that are determinative of a biochemical reoccurrence of prostate cancer
    Patent number: 10501804
    Abstract: The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: December 10, 2019
    Assignees: HudsonAlpha Institute for Biotechnology, Board of Trustees of the Leland Stanford Junior University
    Inventors: Richard M. Myers, James D. Brooks, Marie K. Kirby
  • Methods for detecting expression of lnc-FANCI-2 in cervical cells
    Patent number: 10487365
    Abstract: Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: November 26, 2019
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Zhi-Ming Zheng, Junfen Xu, Jun Zhu, Yanqin Yang, Xiaohong Wang
  • Methods for diagnosing and treating eye-length related disorders
    Patent number: 10487361
    Abstract: The invention provides to methods for diagnosing eye-length related disorders, including myopia. The invention also provides methods for treating and limiting eye-length related disorders, including myopia. In addition, the invention provides certain haplotypes associated with eye-length related disorders, including myopia and Bornholm Eye Disease.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 26, 2019
    Assignee: University of Washinton Through its Center for Commercialization
    Inventors: Jay Neitz, Maureen Neitz
  • Method for determining the survival prognosis of a patient suffering from pancreatic cancer
    Patent number: 10465250
    Abstract: The present invention relates to pancreatic cancer, and more particularly to the survival prognosis of a patient suffering from pancreatic cancer. The invention also aims to determine the suitability of said patient to receive a treatment for pancreatic cancer, in particular a treatment with gemcitabine. The invention also concerns a method for monitoring the effectiveness of a treatment for pancreatic cancer, and advantageously a treatment with gemcitabine, by implementing the method.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: November 5, 2019
    Assignee: ACOBIOM
    Inventor: David Piquemal
  • EML4-ALK translocations in lung cancer
    Patent number: 10435758
    Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: October 8, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Method to use viral and host methylation markers for cervical cancer screening and triage in liquid prep, serum/plasma, and urine: PCR and sequencing based process methods
    Patent number: 10428391
    Abstract: Methods and kits for triaging a human papillomavirus (HPV)-positive woman into colposcopy are disclosed. The methods comprise determining the promoter methylation level of the promoter regions of a group of genes (e.g., viral and host genes) that exhibit increased promoter methylation in women having CIN2+ lesions as compared to women having no intraepithelial lesions or malignancy (NILM).
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: October 1, 2019
    Assignee: The Johns Hopkins University
    Inventors: Rafael Guerrero-Preston, David Sidransky
  • Oligonucleotides for use in determining the presence of in a sample
    Patent number: 10407740
    Abstract: Oligomers useful for determining the presence of Trichomonas vaginalis in a test sample.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: September 10, 2019
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Barbara Susan Weinbaum, Janel M. Dockter, Astrid R. W. Schroder
  • Mitochondrial DNA deletion between about residues 12317-16254 for use in the detection of cancer
    Patent number: 10400290
    Abstract: The present invention relates to methods for predicting, diagnosing and monitoring cancer. The methods comprise obtaining biological samples, extracting mitochondrial DNA (mtDNA) from the samples, quantifying mitochondrial DNA mutation in the sample and comparing the level of mtDNA mutation with a reference value. The methods of the invention may also be effective in screening for new therapeutic agents and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: September 3, 2019
    Assignee: MDNA Life Sciences, Inc.
    Inventors: Ryan Parr, Jennifer Creed, Kerry Robinson, Andrea Maggrah, Katrina Maki, Gabriel Dakubo, Brian Reguly, Andrew Harbottle, Jude Alexander
  • Method for bacterial species identification and strain typing
    Patent number: 10400291
    Abstract: The present disclosure describes a method for identifying a strain or species of bacteria using a single locus sequence typing technique. The single locus useful in the method is the promoter region of the 16S rRNA operon. The method is useful to identify infectious bacteria in a subject, to identifying contaminants in a food source, as well as strain typing and genetic fingerprinting of bacterial families.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: September 3, 2019
    Assignee: The Regents of the University of Michigan
    Inventors: John LiPuma, Theodore Spilker
  • Polynucleotide probe, method for detecting a target nucleic acid by using the same and kit comprising the same
    Patent number: 10400289
    Abstract: The present invention provides a method for detecting a target nucleic acid that comprises a step of providing a sample; contacting the sample with a polynucleotide probe comprising a first sequence and a second sequence complementary to the target nucleic acid; and adding a nuclease for cleaving the second sequence of the polynucleotide probe. The present invention further provides a polynucleotide probe for detecting a target nucleic acid that comprises a first sequence and a second sequence complementary to the target nucleic acid. Moreover, the present invention provides a kit for detecting a target nucleic acid.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 3, 2019
    Assignee: National Taiwan University
    Inventors: Ja-An A. Ho, Amily F. Jou, Yen-Chuan Ou, Shian-Shiang Wang, Itamar Willner, Shih-Lan Hsu
  • Method and reagents for detecting water contamination
    Patent number: 10392671
    Abstract: A method of examining a water supply for microbial contamination involves contacting a water supply with a novel reagent having high specificity for a Legionella microbial species, wherein said reagent does not cross-react, or minimally cross-reacts, with a microbial species other than Legionella. The method further involves detecting, or measuring, a contaminating concentration of a Legionella species in the water supply. Useful reagents comprise at least one nucleotide sequence primer comprising a primer sequence selected from SEQ ID NO: 3-10 or a combination of such primer sequences. The increased specificity of such reagents permits more sensitive detection of microbial contamination.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: August 27, 2019
    Assignee: Dow Global Technologies LLC
    Inventors: Paul O. Schook, Bei Yin
  • Methods for use in combination for the treatment and diagnosis of autoimmune diseases
    Patent number: 10385398
    Abstract: This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: August 20, 2019
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Yun Rose Li, Brendan Keating
  • NRAS gene mutation detection kit
    Patent number: 10385404
    Abstract: This invention relates to a kit for detecting NRAS gene mutation, and this kit can be used to detect cancer-related NRAS gene mutation. The said kit comprises: (1) the internal reference detection reagent, which includes the internal reference gene specific primers, internal reference gene specific probes and dNTP solution; (2) the NRAS mutation detection reagent, which includes the NRAS gene mutant type specific primers, NRAS gene mutant type specific probes, internal control gene specific primers, internal control gene specific probes and dNTP solution; (3) the Taq DNA polymerase; and (4) the NRAS positive quality control.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 20, 2019
    Assignee: Jiaxing ACCB Diagnositc Ltd.
    Inventors: Minli Mo, Hui Li, Zhao Chen, Feng Ding, Jun Li